TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05739097

Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency, coagulation abnormalities
Description: avoid transfusions, where possible

Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency, coagulation abnormalities
Description: avoid transfusions, where possible

Intervention type: DIAGNOSTIC_TEST
Intervention: iron deficiency, coagulation abnormalities
Description: avoid transfusions, where possible
Study: NCT06013865

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: SGLT2 Inhibitor
Study: NCT05238441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: D0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: D0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: D0; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: SCTV01E
Description: D180; intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: D180; intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty
Description: D180; intramuscular injection
Study: NCT05711953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egyfil Pain Lotion
Description: Egyfil is a cosmetic product to be applied to intact skin, useful to attenuate muscolar pain and stiffness, with a novel topical formulation containing hyaluronic acid, SH-Polypeptide-6 and SH-Oligopeptide-1.~The presence of sodium hyaluronate and peptides mixture promotes the pain alleviating activity and soothing properties of the product.
Study: NCT04739670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is a type of chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is platinum based chemotherapy drug
Study: NCT05687773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller on flat display
Description: The LMC is a device with a Universal Serial Bus (USB) device capable of detecting the movement of hands and fingers. It is small in size and you need to connect the USB device to the computer and place your hands above the LMC. First, training will be carried out with the Leap Motion Controller instrument for 5 minutes, for a presentation and interaction with it, in the initial meeting. From the second meeting, the service protocol will be 16 sessions, this time being distributed as: first game lasting 7 minutes, second and third games lasting 6 minutes each and the last game lasting 8 minutes, totaling 27 minutes of intervention. Between games, about 2 minutes of rest was adopted. They were chosen through the website www.leapmotion.com¸ in order to relate them to the functional movements of the upper limbs in daily life tasks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller in Head-Mounted Display
Description: For the immersive group, the same equipment mentioned above Leap Motion Controller will be projected on the Head-Mounted Display model Oculus Quest 2 (Meta Platforms Inc.). The device has binocular displays with Fresnel lenses with a resolution of 1832 by 1920 pixels per eye. It is equipped with a Qualcomm Snapdragon XR2 processor with the refresh rate of 72hz - 120hz and 6GB of RAM. The equipment has a 90º field of view and approximately 500 grams of total weight. The treatment protocol and patient positioning will be the same as previously mentioned, except for the type of projection used. At the 2-minute rest interval between games, the HMD will be removed from the user to change the game in question, returning at the end of this period.
Study: NCT06396169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Exercise
Description: Yoga Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calisthenic Exercise
Description: Calisthenic Exercises
Study: NCT06062667

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: accompany the birth
Description: Fathers will accompany their husbands during the birth process
Study: NCT04186416

Intervention type: OTHER
Intervention: Mostcare® device
Description: The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Mostcare® device
Description: The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Mostcare® device
Description: The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Mostcare® device
Description: The Moscare® system is connected to the patient monitoring devices. Data are collected just before and 5 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Transthoracic cardiac ultrasound
Description: Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Transthoracic cardiac ultrasound
Description: Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Transthoracic cardiac ultrasound
Description: Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.

Intervention type: OTHER
Intervention: Transthoracic cardiac ultrasound
Description: Transthoracic cardiac ultrasound before and 3 minutes after the vascular filling.
Study: NCT04790279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Initiation of amlodipine 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NIFEdipine ER
Description: Initiation of nifedipine ER 30 mg
Study: NCT04858815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yogic breathing
Description: participation in yogic breathing
Study: NCT06228573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
Study: NCT06512675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance combined with cardiovascular training
Description: Participants will undergo a 6-week exercise program designed under the supervision of a board certified sports medicine physician. The exercise program will consist of a 3 day per week schedule: Monday will be lower body resistance training, Wednesday will be aerobic exercise, and Friday will be upper body resistance training. Each session will be approximately up to 1 hour.
Study: NCT06320678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Students Education
Description: Effect of Concept Mapped Blended Learning Self-Directed Learning
Study: NCT06275776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Monocryl Smooth Suture
Description: Monocryl Smooth Suture 3-0 antibacterial with PS-2 needle. Monofilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethicon Vicryl Rapide Braided Suture
Description: Vicryl Rapide Braided Suture 3-0 with FS-2 needle. Multifilament suture, placed subcutaneously to approximate the superficial wound edges. Currently used in standard care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexifuze Indermil Topical Skin Adhesive
Description: Flexifuze Indermil Topical Skin Adhesive. The skin glue is applied after the application of the suture to further seal the wound from the external environment. Currently used in standard care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Prineo Skin Closure System
Description: Dermabond Prineo Skin Closure System. Novel skin closure system consisting of a self-adhesive transparent mesh, over which skin glue is applied as well. This system approximates the wound edges, shields the wound from the external environment, enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Zip Skin Closure System
Description: Stryker Zip Skin Closure System. Novel skin closure system consisting of two self-adhesive strips placed parallel to either side of the wound. Zip tie/Cable tie-like structures running perpendicular to the adhesive strips can be tightened to approximate the wound edges and thusly close the wound. This system enables healthcare professionals to still see the wound and surrounding tissue, and eliminates the invasive aspect of conventional sutures. Currently not used in standard care at the RHOC, but elsewhere it is being used.
Study: NCT06119971

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ACUPRESSURE
Description: Acupressure using disposable devices consisting of a metal microbead and an adhesive material.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUPRESSURE
Description: Acupressure using disposable devices consisting of a metal microbead and an adhesive material.
Study: NCT05646784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebiome
Description: Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
Study: NCT04749628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Epidiolex (cannabidiol) oral solution
Study: NCT06228573

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Yoga
Description: Yoga program: In weeks 2-9, participants will attend twice weekly 1-hour sessions of yoga led by a certified yoga instructor trained in the intervention by collaborator Pearson. Videos will be provided for completion of home sessions. The yoga program is based on the Pain Care Aware certification program.38 Details of the program as well as the training of instructors are provided in the appendices. Briefly, classes will consist of 3 parts: centring and warming up aimed at regulating physiology prior to beginning the yoga postures; yoga postures and guided relaxation.
Study: NCT06025344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PanCytoVir™ 100 mg/mL oral suspension
Description: Single oral dose of 1000 mg (100 mg/mL) under fasted conditions
Study: NCT05832385

Intervention type: RADIATION
Intervention: IMRT
Description: anal cancer: chemoradiotherapy, radiation dose\>50Gy; rectal cancer: chemoradiotheray, radiation dose=50Gy
Study: NCT04749628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Epidiolex (cannabidiol) oral solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ora-sweet SF
Description: Ora-sweet SF placebo
Study: NCT06025344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid 500 mg
Description: Single oral dose of 1000 mg under fasted conditions
Study: NCT06097091

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-management education
Description: A self-management of the FM handbook will be provided. SME will be delivered via weekly video calls over a 6-week period. The video call lasting for 15 minutes, will consist of reviewing the weekly self-management content (5 min), questioning and answering related to the content of the self-management handbook (5 min), and a debriefing session (5 min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pain neuroscience education
Description: Participants in the experimental group will receive a 6-week PNE program. The PNE program that is designed to explain pain to the participants will be implemented via 6 individual face-to-face sessions, each lasting for 45 minutes over a 6-week period. Printed take-home materials will be provided to the participants to enhance learning. The goal of PNE is to increase participants' knowledge about pain to help them reconceptualize their beliefs about pain and decrease perceived threats of pain. The content will be composed according to the second edition of the book, Explain Pain by Butler and Mosley (2013) as well as etiologies of fibromyalgia. Accordingly, the PI has developed the preliminary PNE content.
Study: NCT05805826

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. difficile vaccine (previously studied formulation).
Description: Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: C. difficile vaccine (previously studied formulation).
Description: Toxoid based Clostridioides difficile vaccine (previously studied formulation) given as an intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C. difficile vaccine formulation 1.
Description: C. difficile vaccine formulation 1 given as an intramuscular injection
Study: NCT06053138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester
Description: Supraphysiological levels of ketosis acutely, part 1, and intermittently and longer lasting, part 2, as obtained by ingestion of a ketone monoester dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo vehicle is matched to the ketosis intervention in the experimental arm with regards to taste, volume, viscosity, appearence, and packaging
Study: NCT05770635

Intervention type: DEVICE
Group type: OTHER
Intervention: Embosphere and chemotherapy drug
Description: chemotherapeutic drug + embolic Embosphere;Iodide is selected according to the subject's condition

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyvinyl alcohol embolization microspheres (Huihe Medical) and chemotherapy drug
Description: chemotherapy drug+Polyvinyl alcohol embolization microspheres (Huihe Medical);Iodide is selected according to the subject's condition
Study: NCT06460493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine 3mg
Description: All subjects will receive ensifentrine.
Study: NCT06002555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Peptide analogue of GLP-2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apraglutide
Description: Peptide analogue of GLP-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Peptide analogue of GLP-2
Study: NCT06445647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: core Stability exercise
Description: core stability exercise training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: Deep breathing and diaphragmatic breathing exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercises
Description: Deep breathing and diaphragmatic breathing exercises
Study: NCT05357339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Description: 100ml boluses 20% Albumin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid
Description: 100ml bolus of crystalloid
Study: NCT06000475

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT as described in the treatment manual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: CPT as described in the treatment manual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) + Memory Support
Description: CPT+Memory support will also incorporate frequent and intentional use of strategies to enhance learning and memory of this content.
Study: NCT06426693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental feedback
Description: Participants provided with feedback of target brain activation patterns (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control feedback
Description: Participants provided with control (sham, yoked to another participant) feedback (e.g., thermometer) and will be instructed to try to change the feedback (e.g., decrease the thermometer).
Study: NCT05143593

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: results of SSBD are used to guide antibiotics adjustment
Description: secretions from low resipratory will be obtained on day1,day 3 and day7 after enrollment and detected by SSBD at bedside at once. Antibiotics will be adjusted on the results by experienced doctors.
Study: NCT06370923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Distribution
Description: In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Worker Distribution
Description: Distribution of HIV self tests by community health workers
Study: NCT05960643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and application in breast modeling
Description: BSE application skill evaluation form will be evaluated out of 100 points. The form includes 7 skills: carefully reviewing the model, using three types of pressure, massage, hand position, performing three types of movement, examining each breast for five minutes, and detecting the nodule in the model. A high score is interpreted as a high level of skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: No intervention will be made against people in this group.
Study: NCT05805826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Placebo.
Description: 0.9% sodium chloride solution given as an intramuscular injection
Study: NCT05140876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START mHealth Intervention
Description: The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months.
Study: NCT05911880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet for 14 days in patients with rheumatoid arthritis.
Description: Patients with low to moderate disease activity of rheumatoid arthritis (2.6-5.1 DAS28-CRP) underwent a dietary intervention consisting of an individualized, isocaloric, and plant-based diet with 57% carbohydrates, 25% lipids, and 18% proteins (80% of plant origin) for 14 days, without any modification of their medication regimen and with restricted consumption of processed foods.
Study: NCT05833698

Intervention type: DIAGNOSTIC_TEST
Intervention: Elevation of NLR
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Elevation of NLR
Description: Blood test
Study: NCT05819710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single dose of 5 mg of TS-142
Study: NCT04259047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Regulation for Eyesight and Memory
Description: Participants randomized to DREAM will have 11 in-home visits over 2 years with a CHW, and 4 telehealth visits with a DM nurse educator.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in this group will have 11 in-home CHW visits over 24 months to control for attention. During these visits, the CHW will provide general diabetes education. There will be no telehealth visits.
Study: NCT06101927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole body study and SPECT with [99mTc]Tc-BQ0413
Description: One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.
Study: NCT05819710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Single-dose of 10 mg of TS-142
Study: NCT05683990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamyd
Description: 4 μg (0.1 mL) of Diamyd administered 1 month apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diamyd
Description: 4 μg (0.1 mL) of Diamyd administered 1 month apart.
Study: NCT06539312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP assessment and management of asthma
Description: APPs will be trained to follow NIH guidelines for assessment and management of asthma, and to apply their knowledge to the care of the students. Students will also receive DOT of the morning dose of their controller medication.